Pliant Therapeutics Ownership
| PLRX Stock | USD 13.49 0.15 1.12% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 60.4 M | Current Value 60.7 M | Avarage Shares Outstanding 40.5 M | Quarterly Volatility 15 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pliant |
Pliant Stock Ownership Analysis
About 97.0% of the company shares are owned by institutional investors. The book value of Pliant Therapeutics was at this time reported as 5.68. The company recorded a loss per share of 3.35. Pliant Therapeutics had not issued any dividends in recent years. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. To find out more about Pliant Therapeutics contact MBA MD at 650 481 6770 or learn more at https://pliantrx.com.Besides selling stocks to institutional investors, Pliant Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pliant Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pliant Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pliant Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Pliant Therapeutics Insider Trades History
Roughly 3.0% of Pliant Therapeutics are currently held by insiders. Unlike Pliant Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pliant Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pliant Therapeutics' insider trades
Pliant Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pliant Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pliant Therapeutics backward and forwards among themselves. Pliant Therapeutics' institutional investor refers to the entity that pools money to purchase Pliant Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Polar Capital Holdings Plc | 2024-09-30 | 2 M | Deutsche Bank Ag | 2024-09-30 | 1.5 M | State Street Corp | 2024-09-30 | 1.4 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Ra Capital Management, Llc | 2024-09-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-09-30 | 1.3 M | Franklin Resources Inc | 2024-09-30 | 1 M | Candriam Luxembourg S.c.a. | 2024-09-30 | 833.2 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 817.1 K | Deep Track Capital, Lp | 2024-09-30 | 6 M | Blackrock Inc | 2024-06-30 | 5 M |
Pliant Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pliant Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pliant Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pliant Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pliant Therapeutics Outstanding Bonds
Pliant Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pliant Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pliant bonds can be classified according to their maturity, which is the date when Pliant Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Pliant Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 12th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.